128 related articles for article (PubMed ID: 35970023)
1. Effects of RAS inhibitors on all-site cancers and mortality in the Hong Kong diabetes surveillance database (2002-2019).
Yang A; Wu H; Lau ESH; Shi M; Fan B; Kong AP; Ma RC; Luk AO; Chan JC; Chow E
EBioMedicine; 2022 Sep; 83():104219. PubMed ID: 35970023
[TBL] [Abstract][Full Text] [Related]
2. Time-varying risk associations of renin angiotensin system inhibitors with pneumonia and related deaths in a cohort of 252,616 patients with diabetes (2002-2019).
Yang A; Shi M; Wu H; Lau ES; Fan B; Kong AP; Ma RC; Luk AO; Chan JC; Chow E
Diabetes Res Clin Pract; 2022 Mar; 185():109233. PubMed ID: 35131377
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes following discontinuation of renin-angiotensin-system inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: A prospective cohort study.
Yang A; Shi M; Lau ESH; Wu H; Zhang X; Fan B; Kong APS; Luk AOY; Ma RCW; Chan JCN; Chow E
EClinicalMedicine; 2023 Jan; 55():101751. PubMed ID: 36457651
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study.
Fu EL; Clase CM; Evans M; Lindholm B; Rotmans JI; Dekker FW; van Diepen M; Carrero JJ
Am J Kidney Dis; 2021 May; 77(5):719-729.e1. PubMed ID: 33246024
[TBL] [Abstract][Full Text] [Related]
5. Renin-angiotensin system modulation and outcomes in patients hospitalized for interstitial SARS-CoV2 pneumonia: a cohort study.
Landolfo M; Maino A; Di Salvo E; Fiorini G; Peterlana D; Borghi C
Intern Emerg Med; 2022 Aug; 17(5):1335-1341. PubMed ID: 35064437
[TBL] [Abstract][Full Text] [Related]
6. Renin-angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis.
Bang CN; Greve AM; Køber L; Rossebø AB; Ray S; Boman K; Nienaber CA; Devereux RB; Wachtell K
Int J Cardiol; 2014 Aug; 175(3):492-8. PubMed ID: 25012498
[TBL] [Abstract][Full Text] [Related]
7. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
Kuan YC; Huang KW; Yen DJ; Hu CJ; Lin CL; Kao CH
Int J Cardiol; 2016 Oct; 220():462-6. PubMed ID: 27390970
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: a nationwide study.
Shih CJ; Chu H; Ou SM; Chen YT
Int J Cardiol; 2015 Nov; 199():283-9. PubMed ID: 26218587
[TBL] [Abstract][Full Text] [Related]
10. Renin-Angiotensin System Inhibitors and Major Cardiovascular Events after Sepsis.
Angriman F; Rosella LC; Lawler PR; Ko DT; Martin CM; Wunsch H; Scales DC
Ann Am Thorac Soc; 2023 Mar; 20(3):414-423. PubMed ID: 36251422
[No Abstract] [Full Text] [Related]
11. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
Trifirò G; Massari M; Da Cas R; Menniti Ippolito F; Sultana J; Crisafulli S; Giorgi Rossi P; Marino M; Zorzi M; Bovo E; Leoni O; Ludergnani M; Spila Alegiani S;
Drug Saf; 2020 Dec; 43(12):1297-1308. PubMed ID: 32852721
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers or both in incident end-stage renal disease patients without cardiovascular disease: a propensity-matched longitudinal cohort study.
Ferreira JP; Couchoud C; Gregson J; Tiple A; Glowacki F; London G; Agarwal R; Rossignol P
Nephrol Dial Transplant; 2019 Jul; 34(7):1216-1222. PubMed ID: 30590716
[TBL] [Abstract][Full Text] [Related]
13. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
[TBL] [Abstract][Full Text] [Related]
14. Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis.
Zhao HJ; Li Y; Liu SM; Sun XG; Li M; Hao Y; Cui LQ; Wang AH
Ren Fail; 2016 Jul; 38(6):849-56. PubMed ID: 27055479
[TBL] [Abstract][Full Text] [Related]
15. Impact of renin-angiotensin system inhibitors on the survival of patients with rectal cancer.
Zeman M; Skałba W; Wilk AM; Cortez AJ; Maciejewski A; Czarniecka A
BMC Cancer; 2022 Jul; 22(1):815. PubMed ID: 35879682
[TBL] [Abstract][Full Text] [Related]
16. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus: A PRISMA-compliant systematic review and meta-analysis.
Lv X; Zhang Y; Niu Y; Song Q; Zhao Q
Medicine (Baltimore); 2018 Apr; 97(15):e0256. PubMed ID: 29642146
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers as therapeutic options in the treatment of renal cancer: A meta-analysis.
Asgharzadeh F; Hashemzehi M; Moradi-Marjaneh R; Hassanian SM; Ferns GA; Khazaei M; Avan A
Life Sci; 2020 Feb; 242():117181. PubMed ID: 31863771
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials.
Bangalore S; Kumar S; Kjeldsen SE; Makani H; Grossman E; Wetterslev J; Gupta AK; Sever PS; Gluud C; Messerli FH
Lancet Oncol; 2011 Jan; 12(1):65-82. PubMed ID: 21123111
[TBL] [Abstract][Full Text] [Related]
19. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
[TBL] [Abstract][Full Text] [Related]
20. Influence of Renin-Angiotensin System Inhibitors on Lower-Respiratory Tract Infections in Type 2 Diabetes: The Fremantle Diabetes Study Phase II.
Davis TME; Davis WA
Diabetes Care; 2020 Sep; 43(9):2113-2120. PubMed ID: 32616610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
